ArticleScientific reports2025
Single-cell transcriptomic analysis of blood and bronchoalveolar lavage fluid in progressive fibrosing interstitial lung diseases.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeting the fibrosis-inflammation-oxidative stress axis: multifaceted mechanisms of salidroside in chronic organ fibrosis.Apoptosis : an international journal on programmed cell death · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
This study investigates the pathophysiology of progressive fibrosing interstitial lung disease (PF-ILD) and identifies biomarkers that predict PF-ILD in patients with ILD by analyzing immune cells in both the blood and bronchoalveolar lavage fluid (BALF). This prospective cohort study involved 43 newly diagnosed ILD patients with various connective tissue diseases, from whom BALF and blood samples were collected for analysis. Using Seq-Well, a portable platform for single-cell RNA sequencing, we assessed gene expression in immune cells from both BALF and blood. Additionally, levels of cytokines, chemokines, and complements in the BALF supernatant and plasma were measured using an enzyme-linked immunosorbent assay. In total, 12 patients fulfilled the diagnostic criteria for PF-ILD and exhibited an increase in mononuclear myeloid cells expressing chemokines, such as CCL10 and CCL4, along with plasma cells in their BALF. Additionally, elevated levels of cytokines, including IL-6, CXCL10, and arginase, as well as increased complement activation, were observed in the BALF of patients with PF-ILD. Our findings suggest that active inflammation by macrophages and plasma cells along with complement activation in the lungs may be associated with the progression of pulmonary fibrosis. BALF analysis is beneficial for assessing immune responses and predicting progressive fibrosis in the lungs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.